UroGen Pharma Ltd. Ordinary Shares H.C. Wainwright 28th Annual Global Investment Conference

Well, thanks for having us. We appreciate it. Thanks, Mitchell.

Okay. I think to take a 2-minute going back, our company was founded many years ago in Israel by a group of chemists who were trying to answer a challenge that urologists have. Urologists treat cancers locally, so they give intravesical therapy rather than systemic therapy. Somebody was just calling it cancer lite. Because of that, medicines in the urothelium can't really stay long enough to have a meaningful impact for patients. Therefore, these patients really standard of care is multiple surgeries time after time again, particularly in the group of patients that we have. This group of chemists developed a very elegant solution called RTGel, and it's not called RTGel, it's reverse-thermal hydrogel, where it's actually liquid when it's warm, which is why it's called reverse-thermal.

I mean liquid when it's cold, and as it hits the warm temperature of the body, turns to a gel and then, over time, disintegrates and elutes medicine out to the cavity. In our case, the upper tract or the bladder. That's what our company was really founded on. You talked about what are our priorities. Obviously, right now, we got approval for ZUSDURI, which is for a low-grade intermediate-risk non-muscle invasive bladder cancer, and our launch right now is our number one priority.